Product Development Stories
Will Celularity (USA Stocks:CELU) turn things around in January?
![]() | six days ago at Macroaxis By Rifka Kats |
January often brings a fresh start, and for investors, it can signal a time to reassess portfolios and consider new opportunities. Celularity, a biotechnology firm trading under the ticker CELU on NASDAQ, may catch the eye of savvy investors looking for potential rebounds. Despite a challenging previous quarter with a net income from continuing operations at **$14.2M** and a quarterly earnings growth of -0.93, the company's enterprise value stands at a notable **$101.2M**. Continue Reading...
- CELU Celularity
- Latest Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
- CELU 0.21 -0.01
- Low 0.2
- High 0.21
- Alpha -0.43
- Beta 0.82
- Return On Equity -0.62
- Return On Asset -0.22
- Operating Margin (6.75) %
- Current Valuation 98.2 M
- Shares Outstanding 190.95 M
- Shares Owned By Insiders 37.64 %
- Shares Owned By Institutions 19.42 %
- Number Of Shares Shorted 1.4 M
- Price To Earning 3.08 X
- Price To Book 0.33 X
- Price To Sales 2.60 X
- Revenue 17.98 M
- Gross Profit (1.69 M)
- EBITDA (141.13 M)
- Net Income 14.19 M
- Cash And Equivalents 42.65 M
- Cash Per Share 0.29 X
- Total Debt 65.59 M
- Debt To Equity 0.41 %
- Current Ratio 0.91 X
- Book Value Per Share 0.66 X
- Cash Flow From Operations (137.88 M)
- Short Ratio 2.41 X
- Earnings Per Share (0.47) X
- Target Price 2.5
- Number Of Employees 225
- Beta 0.19
- Market Capitalization 39.34 M
- Total Asset 401.07 M
- Retained Earnings (645.5 M)
- Working Capital (28.59 M)
- Z Score -3.1
- Net Asset 401.07 M
Macroaxis uses a strict editorial review process to publish stories and blog posts. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Michael Smolkin
Hope springs eternal in the human breast, and investors in Vivos Therapeutics Inc (NASDAQ: VVOS) may be cautiously optimistic for a turnaround this January. The company, operating in the Medical Devices sector within the Healthcare industry, has faced significant challenges, reflected in a substantial net income loss of **$23.8 million** and a negative profit margin of **1.06%**. Despite these hurdles, the gross profit stands at a more encouraging **$12.6 million**, suggesting that the company has some underlying strengths to build upon.
over a week ago at Macroaxis By Aina Ster | ![]() |
As we approach December, all eyes are on Check Cap (NASDAQ: CHEK), a prominent player in the Healthcare sector, specifically in the Health Care Equipment & Supplies industry. The company, known for its innovative approach in Diagnostics & Research, has been under the microscope due to its financial performance. Despite reporting a net income loss of $19.1 million and an operating income loss of $20 million, the company's book value stands at a respectable $5.16.
over a week ago at Macroaxis By Vlad Skutelnik | ![]() |
GSE Systems reported a revenue of $47.73 million last year. The company posted a net loss of $15.34 million for the year, with a profit before taxes, overhead, and interest amounting to $11.86 million. The company has a net profit margin of -0.33%, indicating that it has not been effective in controlling expenditures or implementing its pricing strategies.
over a month ago at Macroaxis By Gabriel Shpitalnik | ![]() |
Verizon Communications is currently undervalued, trading at $37.01 per share, with modest growth projections. The company has a beta of 0.5936, suggesting potential diversification benefits within a portfolio. As market returns increase, Verizon Communications' returns are expected to rise, albeit less than the market.
over a month ago at Macroaxis By Ellen Johnson | ![]() |
Cambridge Bancorp (NASDAQ: CATC), a leading player in the Banking Services industry, has been garnering attention from investors due to its promising financial indicators and strategic position. The company, with an enterprise value of $580.8M, has demonstrated a robust profit margin of 28.33% and a return on assets of 0.99%. Despite a slight dip in quarterly earnings growth by 16%, the net income applicable to common shares stands at a solid $52.9M.
over a month ago at Macroaxis By Raphi Shpitalnik | ![]() |
Approximately 23.0% of Aptorum Group's shares are held by company insiders. The insider ownership of Aptorum Group pertains to the portion of the company's equity owned by its officers, directors, relatives of the leadership team, or anyone who has access to non-public information. For our latest analysis of Aptorum, including its current ownership diagnostics, please check out our most recent report.
Extended review
Investing in Aptorum Group stock can be viewed as a promising venture from a product viewpoint.over two months ago at Macroaxis By Gabriel Shpitalnik | ![]() |
News Corp (USA Stocks: NWS), a key player in the Media and Entertainment industry, presents a promising investment opportunity with its robust financial health and strong market presence. The company's gross profit stands at a staggering 4.8B, indicating its strong profitability potential. Despite a slight dip in quarterly revenue growth (-0.09), News Corp's revenue remains robust at 9.9B, demonstrating the company's ability to generate substantial sales.
over two months ago at Macroaxis By Rifka Kats | ![]() |
Phillips 66 (PSX.US), a prominent player in the Oil & Gas Refining & Marketing industry, has been demonstrating a robust performance that solidifies its investment appeal. With a market capitalization of 54.4B, the company has a strong financial footing. The company's net income applicable to common shares stands at a whopping 11B, indicating its profitability.
over three months ago at Macroaxis By Rifka Kats | ![]() |
Arrival Vault (ARVL) has been making waves in the Auto Manufacturers industry, but its financial performance has been less than stellar. The company has a net income applicable to common shares of a loss of 1.1 billion, indicating a significant downturn in profitability. However, with an open price of $1.59 and a recent price change of $0.01, the stock shows potential for growth.
over three months ago at Macroaxis By Vlad Skutelnik | ![]() |